Tag: EMA
First treatment for people with secondary progressive MS in Europe is approved
An important milestone for people with secondary progressive MS in Europe
European Medicines Agency reviews safety of alemtuzumab
EMA conducts safety review of alemtuzumab (Lemtrada)
Cladribine approved in US for people with active secondary progressive MS
FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS
Treatment licensed in US for people with active secondary progressive MS
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
MS organisations across Latin America gather in Mexico for third annual meeting
Third annual meeting (Encuentro) brings together MS organisations from 16 Latin American countries to share learnings and work towards shared solutions to common challenges.